CPSF4 activates telomerase reverse transcriptase and predicts poor prognosis in human lung adenocarcinomas

Molecular Oncology

Volumn 8, Issue 3, 2014, Pages 704-716

  Chen, Wangbing ^a   Qin, Lijun ^b   Wang, Shusen ^a   Li, Mei ^a   Shi, Dingbo ^a   Tian, Yun ^a   Wang, Jingshu ^a   Fu, Lingyi ^a   Li, Zhenglin ^c   Guo, Wei ^c   Yu, Wendan ^c   Yuan, Yuhui ^c   Kang, Tiebang ^a   Huang, Wenlin ^a,d   Deng, Wuguo ^a,d  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

^d Guangzhou Double Bioproduct Inc   (China)

Author keywords

CPSF4; HTERT; Lung cancer; Promoter; Telomerase

Indexed keywords

CALCIUM ION; CLEAVAGE AND POLYADENYLATION SPECIFIC FACTOR 4; MESSENGER RNA; PROTEIN; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; TELOMERASE; TERT PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; ANIMAL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; LUNG; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG; LUNG NEOPLASMS; MICE; PROGNOSIS; PROMOTER REGIONS, GENETIC; TELOMERASE; UP-REGULATION;

EID: 84899476575     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.02.001     Document Type: Article

References (49)

1. Aragaki M., Takahashi K., Akiyama H., Tsuchiya E., Kondo S., Nakamura Y., Daigo Y. Characterization of a cleavage stimulation factor, 3' pre-RNA, subunit 2, 64 kDa (CSTF2) as a therapeutic target for lung cancer. Clin. Cancer Res. An Official J. Am. Assoc. Cancer Res. 2011, 17:5889-5900.
2. Barabino S.M., Hubner W., Jenny A., Minvielle-Sebastia L., Keller W. The 30-kD subunit of mammalian cleavage and polyadenylation specificity factor and its yeast homolog are RNA-binding zinc finger proteins. Genes Dev. 1997, 11:1703-1716.
3. Beitzinger M., Oswald C., Beinoraviciute-Kellner R., Stiewe T. Regulation of telomerase activity by the p53 family member p73. Oncogene 2006, 25:813-826.
4. Bisoffi M., Heaphy C.M., Griffith J.K. Telomeres: prognostic markers for solid tumors. Int. J. Cancer 2006, 119:2255-2260. Journal International du Cancer.
5. Blackburn E.H. Telomerase and Cancer: Kirk A. Landon-AACR prize for basic cancer research lecture. Mol. cancer Res. : MCR 2005, 3:477-482.
6. Blackburn E.H., Greider C.W., Szostak J.W. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat. Med. 2006, 12:1133-1138.
7. Bryan T.M., Cech T.R. Telomerase and the maintenance of chromosome ends. Curr. Opin. Cell Biol. 1999, 11:318-324.
8. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat. Med. 1997, 3:1271-1274.
9. Calvo O., Manley J.L. Strange bedfellows: polyadenylation factors at the promoter. Genes Dev. 2003, 17:1321-1327.
10. Cheng Y.W., Wu T.C., Chen C.Y., Chou M.C., Ko J.L., Lee H. Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. Clin. cancer Res. : An Official J. Am. Assoc. Cancer Res. 2008, 14:7173-7179.
11. Chiu C.P., Harley C.B. Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc. Soc. Exp. Biol. Med. 1997, 214:99-106.
12. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
13. Colgin L.M., Reddel R.R. Telomere maintenance mechanisms and cellular immortalization. Curr. Opin. Gen. Dev. 1999, 9:97-103.
14. Cools J., Stover E.H., Wlodarska I., Marynen P., Gilliland D.G. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr. Opin. Hematol. 2004, 11:51-57.
15. Daniel M., Peek G.W., Tollefsbol T.O. Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012, 498:135-146.
16. de Vries H., Ruegsegger U., Hubner W., Friedlein A., Langen H., Keller W. Human pre-mRNA cleavage factor II(m) contains homologs of yeast proteins and bridges two other cleavage factors. EMBO J. 2000, 19:5895-5904.
17. Deng W.G., Jayachandran G., Wu G., Xu K., Roth J.A., Ji L. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. J.Biol. Chem. 2007, 282:26460-26470.
18. Deng W.G., Tang S.T., Tseng H.P., Wu K.K. Melatonin suppresses macrophage cyclooxygenase-2 and inducible nitric oxide synthase expression by inhibiting p52 acetylation and binding. Blood 2006, 108:518-524.
19. Deng W.G., Wu K.K. Regulation of inducible nitric oxide synthase expression by p300 and p50 acetylation. J.Immunol. 2003, 171:6581-6588.
20. Deng W.G., Zhu Y., Wu K.K. Role of p300 and PCAF in regulating cyclooxygenase-2 promoter activation by inflammatory mediators. Blood 2004, 103:2135-2142.
21. Ducrest A.L., Szutorisz H., Lingner J., Nabholz M. Regulation of the human telomerase reverse transcriptase gene. Oncogene 2002, 21:541-552.
22. Feng J., Funk W.D., Wang S.S., Weinrich S.L., Avilion A.A., Chiu C.P., Adams R.R., Chang E., Allsopp R.C., Yu J., et al. The RNA component of human telomerase. Science 1995, 269:1236-1241.
23. Fujiki T., Miura T., Maura M., Shiraishi H., Nishimura S., Imada Y., Uehara N., Tashiro K., Shirahata S., Katakura Y. TAK1 represses transcription of the human telomerase reverse transcriptase gene. Oncogene 2007, 26:5258-5266.
24. Gotlib J., Cools J., Malone J.M., Schrier S.L., Gilliland D.G., Coutre S.E. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004, 103:2879-2891.
25. Harley C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer 2008, 8:167-179.
26. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., Qin L., Wu X., Zheng Y., Yang Y., Tian W., Zhang Q., Wang C., Zhuang S.M., Zheng L., Liang A., Tao W., Cao X. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19:232-243.
27. Kaufmann I., Martin G., Friedlein A., Langen H., Keller W. Human Fip1 is a subunit of CPSF that binds to U-rich RNA elements and stimulates poly(A) polymerase. EMBO J. 2004, 23:616-626.
28. Kiefer H., Mizutani A., Iemura S., Natsume T., Ando H., Kuroda Y., Mikoshiba K. Inositol 1,4,5-triphosphate receptor-binding protein released with inositol 1,4,5-triphosphate (IRBIT) associates with components of the mRNA 3' processing machinery in a phosphorylation-dependent manner and inhibits polyadenylation. J.Biol. Chem. 2009, 284:10694-10705.
29. Kim M.P., Chen Y., Bekele B.N., Lopez A., Khanna A., Chen J.Q., Spitz M.R., Behrens C., Solis L., Wismach M., Ji L., Wistuba I.I., Roth J.A., Katz R.L. Activating enhancer-binding protein-2beta nucleolar localization predicts poor survival after stage I non-small cell lung cancer resection. Ann. Thorac Surg. 2011, 92:1044-1050.
30. Kleiman F.E., Manley J.L. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. Cell 2001, 104:743-753.
31. Kyo S., Takakura M., Fujiwara T., Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci. 2008, 99:1528-1538.
32. Lantuejoul S., Soria J.C., Moro-Sibilot D., Morat L., Veyrenc S., Lorimier P., Brichon P.Y., Sabatier L., Brambilla C., Brambilla E. Differential expression of telomerase reverse transcriptase (hTERT) in lung tumours. Br. J. Cancer 2004, 90:1222-1229.
33. Liu J.P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J. Official Pub. Fed. Am. Soc. Exp. Biol. 1999, 13:2091-2104.
34. Lu M.H., Liao Z.L., Zhao X.Y., Fan Y.H., Lin X.L., Fang D.C., Guo H., Yang S.M. hTERT-based therapy: a universal anticancer approach (Review). Oncol. Rep. 2012, 28:1945-1952.
35. McCracken S., Fong N., Yankulov K., Ballantyne S., Pan G., Greenblatt J., Patterson S.D., Wickens M., Bentley D.L. The C-terminal domain of RNA polymerase II couples mRNA processing to transcription. Nature 1997, 385:357-361.
36. Milyavsky M., Shats I., Erez N., Tang X., Senderovich S., Meerson A., Tabach Y., Goldfinger N., Ginsberg D., Harris C.C., Rotter V. Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res. 2003, 63:7147-7157.
37. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., Harley C.B., Cech T.R. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.
38. Nemeroff M.E., Barabino S.M., Li Y., Keller W., Krug R.M. Influenza virus NS1 protein interacts with the cellular 30 kDa subunit of CPSF and inhibits 3'end formation of cellular pre-mRNAs. Mol. Cell 1998, 1:991-1000.
39. Rozenblatt-Rosen O., Nagaike T., Francis J.M., Kaneko S., Glatt K.A., Hughes C.M., LaFramboise T., Manley J.L., Meyerson M. The tumor suppressor Cdc73 functionally associates with CPSF and CstF 3' mRNA processing factors. Proc. Natl. Acad. Sci. U S A 2009, 106:755-760.
40. Ruden M., Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat. Rev. 2013, 39:444-456.
41. Saretzki G., Sitte N., Merkel U., Wurm R.E., von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene 1999, 18:5148-5158.
42. Shay J.W., Keith W.N. Targeting telomerase for cancer therapeutics. Br. J. Cancer 2008, 98:677-683.
43. Takakura M., Kyo S., Kanaya T., Hirano H., Takeda J., Yutsudo M., Inoue M. Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 1999, 59:551-557.
44. Tian X., Chen B., Liu X. Telomere and telomerase as targets for cancer therapy. Appl. Biochem. Biotechnol. 2010, 160:1460-1472.
45. Toomey D., Smyth G., Condron C., Kay E., Conroy R., Foley D., Hong C., Hogan B., Toner S., McCormick P., Broe P., Kelly C., Bouchier-Hayes D. Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall cell lung carcinoma: tumor size and lymph node status remain the most important prognostic features. Cancer 2001, 92:2648-2657.
46. Topalian S.L., Kaneko S., Gonzales M.I., Bond G.L., Ward Y., Manley J.L. Identification and functional characterization of neo-poly(A) polymerase, an RNA processing enzyme overexpressed in human tumors. Mol. Cell. Biol. 2001, 21:5614-5623.
47. Weinrich S.L., Pruzan R., Ma L., Ouellette M., Tesmer V.M., Holt S.E., Bodnar A.G., Lichtsteiner S., Kim N.W., Trager J.B., Taylor R.D., Carlos R., Andrews W.H., Wright W.E., Shay J.W., Harley C.B., Morin G.B. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat. Gen. 1997, 17:498-502.
48. Zhang A., Zheng C., Lindvall C., Hou M., Ekedahl J., Lewensohn R., Yan Z., Yang X., Henriksson M., Blennow E., Nordenskjold M., Zetterberg A., Bjorkholm M., Gruber A., Xu D. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 2000, 60:6230-6235.
49. Zhu C.Q., Cutz J.C., Liu N., Lau D., Shepherd F.A., Squire J.A., Tsao M.S. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. Br. J. Cancer 2006, 94:1452-1459.